Oncotelic Therapeutics's EBIT per Share for the
three
months ended in Dec. 2023 was $-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.02.
During the past 3 years, the average EBIT per Share Growth Rate was 77.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 55.60% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 47.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Oncotelic Therapeutics's EBIT per Share or its related term are showing as below:
OTLC'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -26.5 Med: 12.4 Max: 77.3
Current: 77.3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Oncotelic Therapeutics was 77.30% per year. The lowest was -26.50% per year. And the median was 12.40% per year.
OTLC's 3-Year EBIT Growth Rate is ranked better than 98.47% of 1310
companies
in the Biotechnology industry
Industry Median: 3.45
vs OTLC: 77.30
Oncotelic Therapeutics EBIT per Share Historical Data
The historical data trend for Oncotelic Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncotelic Therapeutics (OTCPK:OTLC) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Oncotelic Therapeutics EBIT per Share Related Terms
Thank you for viewing the detailed overview of Oncotelic Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Oncotelic Therapeutics (Oncotelic Therapeutics) Business Description
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OTLC has been successfully added to your 